Harrington Discovery Institute at University Hospitals is now accepting Letters of Intent for the Harrington Scholar-Innovator Award for physician-scientists. The award offers successful applicants multiple opportunities for funding in addition to expertise from pharma-experienced leaders with a track record of bringing drugs to market. Intellectual property rights are retained by the award recipient or their institution.
This scholar award recognizes outstanding physician-scientists whose work has potential to advance standard of care. Each year up to 12 Harrington Scholar-Innovators are chosen. The award includes:
- Two-year grant
- $100,000 guaranteed grant award
- Opportunity to compete for acceleration funds up to $300,000
- Opportunity to qualify for investment funds typically up to $2MM
- A personalized team of drug developers and project manager for each award recipient
- Expert business, commercialization and clinical development advice
- Regulatory assistance
- Intellectual property (IP) review and advice
- Assistance identifying and securing additional financial support based on project needs
Deadlines:
- Mandatory LOI Submission Deadline: June 5, 2024
- Full Proposal Deadline for those Invited: Aug. 7, 2027
The Harrington Scholar-Innovator award selection committee seeks breakthrough discoveries defined by innovation, creativity and potential for clinical impact, including:
- Discoveries deemed to address unmet medical needs
- Modulators of novel targets
- Potential to be developed into a commercial program
- Strong intellectual property (IP) or protection strategy
- May be a small molecule, biologic, or other therapeutic modality
- Diagnostics or devices only acceptable as part of a therapeutic development project
- MD or MD/PhD (or equivalent)
- Faculty position at an accredited academic medical center, university or research institution in the US or Canada, and conduct the majority of his/her/their research at that institution
- A project must have a single Principal Investigator (PI), who is responsible for project oversight and financial management. The PI may engage collaborators, core labs or commercial CROs to execute any portion of the project.
- Past recipients of Harrington awards may submit new and distinct proposals, but may not seek additional support for previously funded projects.
2024: Christopher Holley, MD, PhD – Duke University
Non-Coding RNA to Treat Atherosclerosis